U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H26ClN3O3.C4H6O4
Molecular Weight 485.958
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRUCALOPRIDE SUCCINATE

SMILES

OC(=O)CCC(O)=O.COCCCN1CCC(CC1)NC(=O)C2=CC(Cl)=C(N)C3=C2OCC3

InChI

InChIKey=QZRSNVSQLGRAID-UHFFFAOYSA-N
InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)

HIDE SMILES / InChI

Molecular Formula C18H26ClN3O3
Molecular Weight 367.87
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H6O4
Molecular Weight 118.088
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin 5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RESOLOR
PubMed

PubMed

TitleDatePubMed
Serotoninergic neuroenteric modulators.
2001 Dec 15
Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.
2001 Feb
The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.
2001 Jun 29
The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein.
2001 Nov 30
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
2002
Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation.
2002 Apr
Irritable bowel syndrome: update on pathogenesis and management.
2002 Jan-Mar
The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers.
2002 Mar
Gateways to clinical trials.
2002 Oct
[Visceral hypersensitivity: a concept within our reach].
2003 Jan
The serotonin 5-HT4 receptor and the amyloid precursor protein processing.
2003 Jan-Feb
Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.
2003 Jun
Gateways to clinical trials.
2003 Oct
Gastrointestinal motility disorders and gastrointestinal prokinetic therapy.
2003 Sep
The treatment of chronic constipation in elderly people: an update.
2004
New and emerging treatment options for chronic constipation.
2004
Presynaptic modulation of cholinergic and non-cholinergic fast synaptic transmission in the myenteric plexus of guinea pig ileum.
2004 Jun
Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists.
2005 Apr
Rationale for using serotonergic agents to treat irritable bowel syndrome.
2005 Apr 1
Increased cholinergic contractions of jejunal smooth muscle caused by a high cholesterol diet are prevented by the 5-HT4 agonist--tegaserod.
2006 Feb 23
Fading of 5-HT4 receptor-mediated inotropic responses to 5-hydroxytryptamine is caused by phosphodiesterase activity in porcine atrium.
2006 Jan
5HT4 agonists inhibit interferon-gamma-induced MHC class II and B7 costimulatory molecules expression on cultured astrocytes.
2006 Oct
5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice.
2007 Apr
The long and short of a constipation-reducing medication.
2008 May 29
A placebo-controlled trial of prucalopride for severe chronic constipation.
2008 May 29
New treatments for irritable bowel syndrome in women.
2008 Nov
Gateways to clinical trials.
2008 Oct
Gateways to clinical trials.
2008 Sep
Management of constipation in the elderly: emerging therapeutic strategies.
2008 Sep 7
Prucalopride for chronic constipation.
2009 Dec
Translating 5-HT receptor pharmacology.
2009 Dec
Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
2009 Feb 1
Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach.
2009 Jan
Gateways to clinical trials.
2009 Mar
Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives.
2009 Mar
Investigations into the binding affinities of different human 5-HT4 receptor splice variants.
2010
Effect of ICU interventions on gastrointestinal motility.
2010 Apr
Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation.
2010 Feb
Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat.
2010 Feb 16
New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
2010 Jun
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
2010 Jun 8
Hyperfunction of muscarinic receptor maintains long-term memory in 5-HT4 receptor knock-out mice.
2010 Mar 4
Influence of 5-HT4 receptor activation on acetylcholine release in human large intestine with endometriosis.
2010 May
Emerging pharmacologic therapies for irritable bowel syndrome.
2010 Oct
Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation.
2010 Sep
A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation.
2010 Sep
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Adults: 2 mg once daily with or without food, at any time of the day.
Route of Administration: Oral
In Vitro Use Guide
Cell shortening and real-time Ca(2+) measurements were processed on field-stimulated intact cardiomyocytes with the selective 5-HT4R agonist, prucalopride (1 uM).
Substance Class Chemical
Created
by admin
on Tue Oct 22 01:43:08 UTC 2019
Edited
by admin
on Tue Oct 22 01:43:08 UTC 2019
Record UNII
4V2G75E1CK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRUCALOPRIDE SUCCINATE
MART.   USAN   WHO-DD  
USAN  
Official Name English
PRUCALOPRIDE SUCCINATE [USAN]
Common Name English
PRUCALOPRIDE SUCCINATE [MART.]
Common Name English
MOTEGRITY
Brand Name English
PRUCALOPRIDE (AS SUCCINATE)
Common Name English
PRUCALOPRIDE SUCCINATE [WHO-DD]
Common Name English
BUTANEDIOIC ACID, COMPD. WITH 4-AMINO-5-CHLORO-2,3-DIHYDRO-N-(1-(3-METHOXYPROPYL)-4-PIPERIDINYL)-7-BENZOFURANCARBOXAMIDE (1:1)
Common Name English
RESOLOR
Brand Name English
R-108512
Code English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Tue Oct 22 01:43:08 UTC 2019 , Edited by admin on Tue Oct 22 01:43:08 UTC 2019
EMA ASSESSMENT REPORTS RESOLOR (AUTHORIZED: CONSTIPATION)
Created by admin on Tue Oct 22 01:43:08 UTC 2019 , Edited by admin on Tue Oct 22 01:43:08 UTC 2019
Code System Code Type Description
PUBCHEM
9870009
Created by admin on Tue Oct 22 01:43:08 UTC 2019 , Edited by admin on Tue Oct 22 01:43:08 UTC 2019
PRIMARY
EVMPD
SUB28850
Created by admin on Tue Oct 22 01:43:08 UTC 2019 , Edited by admin on Tue Oct 22 01:43:08 UTC 2019
PRIMARY
NCI_THESAURUS
C152112
Created by admin on Tue Oct 22 01:43:08 UTC 2019 , Edited by admin on Tue Oct 22 01:43:08 UTC 2019
PRIMARY
CAS
179474-85-2
Created by admin on Tue Oct 22 01:43:08 UTC 2019 , Edited by admin on Tue Oct 22 01:43:08 UTC 2019
PRIMARY
ChEMBL
CHEMBL117287
Created by admin on Tue Oct 22 01:43:08 UTC 2019 , Edited by admin on Tue Oct 22 01:43:08 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY